Metastatic Brain Tumours from Oesophageal Carcinoma: Neuro-Imaging and Clinicopathological Characteristics in Japanese Patients

Takeshima, Hideo; Kuratsu, Jun Ichi; Nishi, Toru; Soyama, Naohiro; Miura, Masaki; Masumitsu, Tsutomu; Ushio, Yukitaka

doi:10.1007/s007010170135

Cited by 18 publications

(22 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In those cases, BM was often misdiagnosed as meningitis, a pituitary tumor, or glioma. BM predominantly occurs after treatment [4,6,7,18,[20][21][22][23] based on the results of BM occurrence at 5 [27] , 6.7 [17] , 8.4 [28] , or 10 mo [29] after treatment, ranging from 4 to 57 mo. Clinical staging and adjuvant therapy are considered to be associated with BMEC, but the factors influencing the interval from treatment to BMEC occurrence have not been clarified.…”

Section: Misdiagnosis Of Bmec That Occurs Earlier Than the Diagnosis mentioning

confidence: 99%

“…In recent decades, additional CT findings of BM have been reported. Among those reports, that by Takeshima and colleagues [28] of CT data from eight BMEC cases is considered as a classic report even today. Their study reported that CT displayed enhanced thin-walled cystic lesions in four of six squamous cell carcinoma cases and in both cases of small cell carcinoma.…”

Section: Uncertain Value Of the Unique Imaging Characteristics Of Bmmentioning

confidence: 99%

See 1 more Smart Citation

Incidence and treatment of brain metastasis in patients with esophageal carcinoma

Feng¹,

Zhang²,

Zheng³

et al. 2015

WJG

View full text Add to dashboard Cite

Brain metastasis from esophageal carcinoma (BMEC) is very rare, but its incidence has increased in the United States, Japan, China and other counties. Reports on BMEC have largely been focused on examining whether adjuvant therapy for esophageal cancer influences the survival duration of BMEC patients and on the imaging characteristics of BMEC determined using new medical equipment. The difference between different pathological types of esophageal cancer, especially adenocarcinoma and squamous cell carcinoma, is one important factor used to assess the influence of BMEC. Adjuvant therapy, including radiotherapy and chemotherapy, for esophageal cancer with different characteristics in different countries may affect BMEC treatment outcomes. The degree of popularization of advanced medical equipment is a major concern related to the prevalence of BMEC. Furthermore, targeted BMEC treatment is under development in developed countries. In this article, we reviewed the debate surrounding BMEC and analyzed BMEC studies from different perspectives.

show abstract

Section: Misdiagnosis Of Bmec That Occurs Earlier Than the Diagnosis mentioning

confidence: 99%

Section: Uncertain Value Of the Unique Imaging Characteristics Of Bmmentioning

confidence: 99%

Incidence and treatment of brain metastasis in patients with esophageal carcinoma

Feng¹,

Zhang²,

Zheng³

et al. 2015

WJG

View full text Add to dashboard Cite

show abstract

“…The survival periods once PTC is diagnosed with a BM as well as its individual treatments are presented in Table 3. Table 2 Average survival periods in months following specific treatment of brain metastases originating from thyroid carcinoma [16,17,23,[115][116][117][118] [32][33][34]. In the Western population, esophageal adenocarcinomas are more frequent.…”

Section: Survival and Outcomementioning

confidence: 99%

Modern management of rare brain metastases in adults

et al. 2011

View full text Add to dashboard Cite

Brain metastases (BM) represent the main cause of intracranial neoplasms in adults, while being relatively less common in children. Today, better treatment options of the primary malignancy lead to higher remission rates as well as prolonged stable clinical conditions. This may in part explain the increased incidence of BM. Morbidity and mortality rates in patients with malignancies deteriorate significantly in cases of metastatic involvement of the central nervous system. Nowadays, especially modern management using surgical, medical, and radiotherapeutic options for treatment of BM tends to improve survival rates and enhance quality of life. Nonetheless, almost all treatment options are considered as palliative. In this review, we outline current knowledge of the incidence, diagnostic facilities, and therapeutic management of rare BM, with consideration of the basic aspects of the primary malignancy.

show abstract

“…However, with the increased use of positron emission tomography (PET) at initial staging, along with advances in neuroimaging, the incidence of BM has gradually increased, as reported in the literature (6,7). Due to the rarity of BM in patients with EC, there is no standardized treatment for these patients.…”

Section: Introductionmentioning

confidence: 99%

“…Due to the rarity of BM in patients with EC, there is no standardized treatment for these patients. The survival time of patients with EC and metastasis to the brain ranges from 2 weeks to 25 months, depending on the extent of disease and the treatment modalities employed (7,8). Previously, it was demonstrated that patients with one to three BMs had improved survival rates with advanced treatment modalities (9).…”

Section: Introductionmentioning

confidence: 99%

Outcomes of aggressive treatment in esophageal cancer patients with synchronous solitary brain metastasis

Onal

Yıldırım

Güler

2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. The aim of the present study was to investigate the outcomes of esophageal cancer (EC) patients with isolated synchronous brain oligometastasis (oligo-BM) treated with chemoradiotherapy (CRT) of the primary site and localized treatment of the BM with surgery, radiotherapy (RT) or radiosurgery. Of 125 EC patients investigated, seven patients (6%) had solitary BM. Six patients were diagnosed prior to, and one patient was diagnosed during, treatment. All patients were treated with neoadjuvant chemotherapy and whole-brain RT (WBRT) for BM. All but one patient received definitive CRT with a median RT dose of 50.4 Gy using conventional fractionation RT. The median age at diagnosis was 59 years (range, 48-77 years). Six patients succumbed to mortality, and one continued to receive systemic chemotherapy at the last visit. The median survival time of the patients was 18.9 months (range, 10.0-27.2 months). Median time to progression after completion of the treatments was 8 months (range, 3-9 months). Two patients had progression of the primary tumor, and one patient had progression of the BM. The neurological status of three patients with BM who were identified during the staging work-up did not deteriorate as a consequence of WBRT. In conclusion, the present study has demonstrated that aggressive treatment of the primary tumor and oligo-BM in patients with EC may prolong the survival time. IntroductionEsophageal cancer (EC) is one of the most common tumors of the gastrointestinal system. The prognosis of EC patients is relatively poor, since the majority of patients are diagnosed at an advanced stage. The most common metastatic sites include the lungs, liver, and bones (1). The incidence of brain oligometastasis (oligo-BM) is extremely rare (1-3% incidence in clinical series) (2,3). The majority of patients with BM are diagnosed at an advanced clinical stage, and the majority of BMs tend to occur together with other organ metastases (2,4,5).Since brain imaging as part of a metastasis work-up is not routinely performed, detection of solitary BM at diagnosis is difficult. However, with the increased use of positron emission tomography (PET) at initial staging, along with advances in neuroimaging, the incidence of BM has gradually increased, as reported in the literature (6,7). Due to the rarity of BM in patients with EC, there is no standardized treatment for these patients. The survival time of patients with EC and metastasis to the brain ranges from 2 weeks to 25 months, depending on the extent of disease and the treatment modalities employed (7,8). Previously, it was demonstrated that patients with one to three BMs had improved survival rates with advanced treatment modalities (9). Therefore, an aggressive treatment approach may be effective for only a limited number of patients with good performance status and solitary metastasis. However, it is important to make balanced clinical decisions for treatment planning; specifically, how to identify patients with oligometastasis who would benefit from localized the...

show abstract

Metastatic Brain Tumours from Oesophageal Carcinoma: Neuro-Imaging and Clinicopathological Characteristics in Japanese Patients

Abstract: Among Japanese, the vast majority of primary esophageal cancers are squamous cell carcinomas. Therefore, MRI findings of a cystic tumour with a thin enhanced rim may alert one to the possibility of a metastatic brain tumour from the esophagus.

Cited by 18 publications

References 8 publications

Incidence and treatment of brain metastasis in patients with esophageal carcinoma

Incidence and treatment of brain metastasis in patients with esophageal carcinoma

Modern management of rare brain metastases in adults

Outcomes of aggressive treatment in esophageal cancer patients with synchronous solitary brain metastasis

Contact Info

Product

Resources

About